Achillion Pharma (ACHN) Misses Q4 EPS by 3c

Achillion Pharma (NASDAQ: ACHN) reported Q4 EPS of ($0.21), $0.03 worse than the analyst estimate of ($0.18).

2015 Financial Guidance

At December 31, 2014, Achillion had cash, cash equivalents, marketable securities and interest and subscription receivables of approximately $159.2 million. Achillion completed a public offering of common stock on February 18, 2015, and received net proceeds of $132.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.

The Company expects that research and development expenses during 2015 will be approximately $85 - $95 million and that net cash used in operating activities in 2015 will be approximately $100 - $110 million based on current operating plans, anticipated timelines and the estimated cost of clinical trials and product development programs. The net loss per share is anticipated to approximate $0.95 per share.

For earnings history and earnings-related data on Achillion Pharma (ACHN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15